• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

    261.58 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,454
    Open 261.58
    Bid (Size) 262.00 (100)
    Ask (Size) 267.00 (100)
    Prev. Close 261.58
    Today's Range 261.58 - 261.58
    52wk Range 160.86 - 271.89
    Shares Outstanding 57,152,295
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate ↗
    Via Chartmill
    News headline image
    What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
    Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +22.6%
    +22.6%
    1 Month
    +9.2%
    +9.2%
    3 Month
    +18.6%
    +18.6%
    6 Month
    +25.2%
    +25.2%
    1 Year
    +51.2%
    +51.2%

    More News

    Read More
    News headline image
    Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
    Via MarketMinute
    Topics Economy
    News headline image
    Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
    Via Chartmill
    News headline image
    Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
    Via The Motley Fool
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
    Via Benzinga
    News headline image
    A Look Ahead: Ascendis Pharma's Earnings Forecast ↗
    Via Benzinga
    News headline image
    $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
    Via Chartmill
    News headline image
    Why Dyne Therapeutics Stock Was Crushing it This Week ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    News headline image
    Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
    Via Benzinga
    News headline image
    Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
    Via Benzinga
    News headline image
    Looking Into Ascendis Pharma AS's Recent Short Interest ↗
    Via Benzinga
    News headline image
    Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗
    Via Chartmill
    News headline image
    What Does the Market Think About Ascendis Pharma AS? ↗
    Via Benzinga

    Frequently Asked Questions

    Is Ascendis Pharma A/S - Ordinary Share publicly traded?
    Yes, Ascendis Pharma A/S - Ordinary Share is publicly traded.
    What exchange does Ascendis Pharma A/S - Ordinary Share trade on?
    Ascendis Pharma A/S - Ordinary Share trades on the Nasdaq Stock Market
    What is the ticker symbol for Ascendis Pharma A/S - Ordinary Share?
    The ticker symbol for Ascendis Pharma A/S - Ordinary Share is ASND on the Nasdaq Stock Market
    What is the current price of Ascendis Pharma A/S - Ordinary Share?
    The current price of Ascendis Pharma A/S - Ordinary Share is 261.58
    When was Ascendis Pharma A/S - Ordinary Share last traded?
    The last trade of Ascendis Pharma A/S - Ordinary Share was at 06/25/26 04:00 PM ET
    What is the market capitalization of Ascendis Pharma A/S - Ordinary Share?
    The market capitalization of Ascendis Pharma A/S - Ordinary Share is 14.95B
    How many shares of Ascendis Pharma A/S - Ordinary Share are outstanding?
    Ascendis Pharma A/S - Ordinary Share has 15B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.